- Home
- PIII vs OSRH Comparison
PIII vs OSRH Comparison
Compare PIII & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- OSRH
- Stock Information
- Founded
- PIII 2015
- OSRH N/A
- Country
- PIII United States
- OSRH United States
- Employees
- PIII N/A
- OSRH N/A
- Industry
- PIII Medical/Nursing Services
- OSRH
- Sector
- PIII Health Care
- OSRH
- Exchange
- PIII Nasdaq
- OSRH Nasdaq
- Market Cap
- PIII 20.8M
- OSRH 19.0M
- IPO Year
- PIII N/A
- OSRH N/A
- Fundamental
- Price
- PIII $6.78
- OSRH $0.53
- Analyst Decision
- PIII Buy
- OSRH
- Analyst Count
- PIII 2
- OSRH 0
- Target Price
- PIII $16.25
- OSRH N/A
- AVG Volume (30 Days)
- PIII 12.0K
- OSRH 1.3M
- Earning Date
- PIII 08-14-2025
- OSRH 08-14-2025
- Dividend Yield
- PIII N/A
- OSRH N/A
- EPS Growth
- PIII N/A
- OSRH N/A
- EPS
- PIII N/A
- OSRH N/A
- Revenue
- PIII $1,461,823,000.00
- OSRH N/A
- Revenue This Year
- PIII N/A
- OSRH N/A
- Revenue Next Year
- PIII $7.92
- OSRH N/A
- P/E Ratio
- PIII N/A
- OSRH N/A
- Revenue Growth
- PIII 4.20
- OSRH N/A
- 52 Week Low
- PIII $5.80
- OSRH $0.52
- 52 Week High
- PIII $30.50
- OSRH $13.40
- Technical
- Relative Strength Index (RSI)
- PIII 48.91
- OSRH N/A
- Support Level
- PIII $6.42
- OSRH N/A
- Resistance Level
- PIII $7.11
- OSRH N/A
- Average True Range (ATR)
- PIII 0.55
- OSRH 0.00
- MACD
- PIII -0.03
- OSRH 0.00
- Stochastic Oscillator
- PIII 45.35
- OSRH 0.00
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.